The Food and Drug Administration announced Tuesday that it would limit access to COVVI-19 vaccines in the future for people aged 65 and over and others who are at high risk of becoming seriously sick if they are infected and will force manufacturers to carry out clinical trials to show whether vaccines are beneficial for young adults and healthy children.
After weeks to report a change in reflection, the new FDA leaders and the agency division that regulate vaccines published a comment in the New England Journal of Medicine, developing their plan for future use of coated vaccines.
Commissioner Marty Makary and Vinay Prasad, director of the Center for Biologics Evaluation and Research, argued that the American approach to recommend a vaccination coded for all those aged 6 months and more was out of step with the rest of the world and may no longer be necessary, given that many people have developed a certain immune protection at the Sars-Cov-2 virus through the vaccinations, infections, or both.
This article is exclusive to stat + subscribers
Unlock this article – plus an in -depth analysis, newsletters, premium events and news alerts.
Do you already have an account? Connect
Show all plans
